health innovation

Pancreatic cancer is one of the deadliest forms of cancer, and it’s on track to become even more lethal. By 2030, it is projected to be the second-leading cause of cancer deaths globally. Often diagnosed at a late stage, the disease is notoriously difficult to treat, with survival rates remaining dismally low despite decades of research.

Dietary changes could reduce the pain of endometriosis for half of those living with the disease, a major new international study suggests.

A recent randomized controlled trial published in the journal Nutrients has found that pomegranate extract (PE) supplementation may offer significant health benefits to adults over the age of 55, particularly in reducing systolic blood pressure and key markers of inflammation. This research contributes to the growing body of evidence supporting the use of non-pharmaceutical strategies to promote healthy ageing.

The World Health Organization (WHO) reports that more than 40% of adults worldwide are overweight or obese—a figure that has nearly tripled since 1975. This rising prevalence of obesity is not only a public health crisis but also a driving force behind the search for effective weight loss treatments. Excess body weight is strongly linked to an increased risk of type 2 diabetes, cardiovascular disease, and other metabolic disorders, making obesity one of the greatest challenges in modern medicine.

Postbiotics—bioactive compounds produced by beneficial microbes during the fermentation of prebiotic substrates—are emerging as a promising alternative in the field of gut health. Unlike probiotics, which involve the ingestion of live microorganisms, postbiotics consist of non-living microbial cells, cellular components, and metabolites such as bacteriocins, exopolysaccharides, and peptidoglycan. This breakthrough has garnered significant attention as scientists and industry leaders seek safer, more stable, and longer-lasting solutions to promote gastrointestinal well-being and overall health.

A groundbreaking study published in the journal Aging (Aging-US) on February 18, 2025, explores the potential of platelet-rich plasma (PRP) in improving ovarian function and enhancing egg quality in women with diminished ovarian reserve. The study, conducted by researchers from IVIRMA New Jersey, Yale School of Medicine, Yale University, and Acibadem Mehmet Ali Aydinlar University, offers hope to women struggling with infertility and poor ovarian response (POR) during in vitro fertilization (IVF) treatment.